| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
CURIS INC [ CRIS ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 01/18/2015 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock, par value $0.01 per share | 09/07/2016 | 09/07/2016 | P | 10,208,333 | A | $2.4 | 27,328,464 | D | ||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
|
| Explanation of Responses: |
| Remarks: |
| Aurigene Discovery Technologies Limited ("Aurigene") has acquired from the Issuer an additional 10,208,333 shares of Common Stock, par value $0.01 per share, of the Issuer at a purchase price of $2.40 per share. 1. This Form 4 is being filed jointly by (i) Aurigene Discovery Technologies Limited ("Aurigene"), which (after giving effect to the acquisition of an additional 10,208,333 shares as described above) directly holds 27,328,464 shares of Common Stock of the Issuer (the "Reported Securities"), (ii) Dr. Reddy's Laboratories Ltd. ("DRL"), as the parent company and 100% owner of Aurigene, and (iii) Dr. Reddy's Holdings Ltd. ("DRHL"), in the event that it could be deemed to "beneficially own" the Reported Securities as the result of its ownership of voting securities of DRL. 2. In the event that DRHL could be deemed to "beneficially own" the Reported Securities as the result of its ownership of voting securities of DRL, its proportional pecuniary interest in such Reported Securities would be approximately 24.262%, which would represent approximately 6,630,545 shares of Common Stock of the Issuer. 3. The filing of this Form 4 shall not be deemed an admission for the purposes of Section 16 or any other purpose that any reporting person is the beneficial owner of any Reported Securities, and DRHL expressly disclaims that it is the beneficial owner of any of the Reported Securities. |
| AURIGENE DISCOVERY TECHNOLOGIES LIMITED, By: /s/ Ashish Lath, Name: Ashish Lath, Title: Director of Finance | 09/08/2016 | |
| DR. REDDY'S LABORATORIES LIMITED, By: /s/ Saumen Chakraborty, Name: Saumen Chakraborty, Title: President and Chief Financial Officer | 09/08/2016 | |
| DR. REDDY'S HOLDINGS LIMITED, By:/s/ G V Prasad, Name: G V Prasad, Title: Director | 09/08/2016 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||